Belenos Biosciences Inc., a private, clinical-stage biotechnology company today announced that its China partner Keymed Biosciences has reported topline results from a Phase 1b study (n=46) of BEL512 ...
Upstream Bio is presenting at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025, which highlights the company's commitment to disseminating important research and gaining ...
– Pharmacology modeling data presented at the European Academy of Allergy & Clinical Immunology (EAACI) Congress describe mechanistic insights for greater potency with verekitug compared to ...
Hosted on MSN
Upstream Bio Presents New Structural Data on Verekitug, Highlights Unique TSLP Receptor Targeting
Upstream Bio Inc. (NASDAQ:UPB) is one of the best hot stocks to invest in. On September 30, Upstream Bio presented new structural and mechanistic data for its therapeutic candidate, verekitug, at the ...
A phase 2 asthma study of Upstream Bio’s TSLP receptor antagonist has hit its primary endpoint. But, with only the 12-week regimen achieving a Tezspire-like reduction in the annualized asthma ...
Please provide your email address to receive an email when new articles are posted on . Patients with asthma saw a 23% reduction in FeNO with treatment. Most adverse events were mild, with no serious ...
-- BEL512: -- Support for Extended Dosing Intervals: Subcutaneous BEL512 (CM512) demonstrated long half-life of up to 70 days -- Clinical Improvements: Patients dosed on Day 1, Day 15, and Day 29 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results